About Us
Our team is passionate about supporting diagnostic and therapeutic development for both research organisations and businesses including those operating in the pharmaceutical industry.
With our collective expertise in nucleic acid synthesis chemistry and years of experience in oligonucleotide manufacturing from our advisory team and board members, Syngenis leverage the best global expertise to supply our customers with high quality oligonucleotides.
All of our products are Australian made and owned and manufactured in Western Australia.
Our Story
After 6 years of running the oligonucleotide synthesis service out of the Murdoch University campus in Western Australia, Syngenis Pty Ltd was established in late 2020. The company moved to its own larger facility in Bentley Technology Park, Western Australia with support from initial investors.
Syngenis is well set with highly experienced synthesis chemists and other supporting staff to provide high quality oligonucleotides in Australia, New Zealand, and the rest of the world.
Board Members
Chairman
Dr. Martin Blake is a practising radiologist and experienced healthcare executive. He is currently the Chairman of the PerthRadClinic Foundation and until recently served as Chairman of Resonance Health Ltd (ASX:RHT) and holds multiple board roles, with expertise spanning medical imaging, medical devices, technology commercialisation, mergers and acquisitions, and hospital-sector leadership.
Managing Director
Thomas Hanly is a biotechnology founder and commercial strategist with experience across diagnostics, life sciences, and emerging technologies. He was recently a founding director of Nexsen Limited (ASX:NXN) and previously served as the inaugural Managing Director of Singular Health Group Limited (ASX:SHG), specialising in scaling science-led businesses into investable commercial platforms.
Founder, Director & Chief Technology Officer
Rakesh N. Veedu is a Professor and Head of Nucleic Acid Therapeutics Group at Murdoch University & Perron Institute. He is a recognised expert in DNA, RNA, and chemically modified oligonucleotide synthesis. He has led a state-of-the-art synthesis facility in Perth for over six years, published more than 100 peer-reviewed articles, authored a book, and is an inventor on multiple nucleic acid–related patents.
Director
Gavin Ball is an experienced business manager who adds strength across the organisations he supports. He has over 30 years’ hands-on experience in start-up formation, commercial development, growth, and business management, with proven expertise in leadership, finance, governance, and sales and marketing across ASX-listed and private companies.